All In Biotech

Drug Trial Radar · NCT07123454

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Sep 24, 2025

Primary completion

Jul 4, 2028

Study completion Feb 15, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

  • AZD4512Drug

    AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion

  • SurovatamigDrug

    Surovatamig (AZD0486) is a 'bispecific' antibody to be administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with dose-limiting toxicities (DLTs) during the DLT periodTime frame: Up to 4 weeks
  2. Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
  3. Frequency of SAEs/AEs leading to discontinuation of study treatmentTime frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
  4. Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parametersTime frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Irvine, California · Suspended

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    New York, New York · Suspended

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Cleveland, Ohio · Withdrawn

  • Research Site

    Myrtle Beach, South Carolina · Withdrawn

  • Research Site

    Franklin, Tennessee · Recruiting

  • Research Site

    Macquarie University, Australia · Not yet recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Bologna, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Bunkyō City, Japan · Recruiting

  • Research Site

    Kōtoku, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Taichung, Taiwan · Recruiting

  • Research Site

    Taipei, Taiwan · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.